comprising a cell expressing a chimeric receptor in the manufacture of a medicament for use in combination therapy for treating a cancer, wherein said medicament is to be administered in combination with an antigen binding molecule, wherein

the antigen binding molecule comprises a linker that is cleavable by protease, and has the ability to bind to a target antigen after the cleavage of the linker, and

the chimeric receptor comprises an extracellular binding domain, a transmembrane domain and an intracellular signal transduction domain, and the extracellular binding domain has the ability to bind to the antigen binding molecule after cleavage of the linker, and is capable of binding to a cell expressing the target antigen via binding to the antigen binding molecule after the cleavage of the linker, wherein the antigen binding molecule comprises variable and constant regions of an antibody, and a linker that is cleavable by protease, wherein the antibody is selected from an IgG antibody, an IgG antibody-like molecule and a heavy chain antibody, and the antigen binding molecule obtained through the cleavage of the linker by the protease comprises an antigen binding domain and a portion of the cleaved linker, and a) wherein in the antigen binding molecule, the linker that is cleavable by protease is located near the boundary between the variable region and the constant region or near the boundary between CH1 and CH2 in the constant region, b) wherein in the antigen binding molecule, the linker that is cleavable by protease is located near a hinge region, or c) wherein the antigen binding molecule is an antibody or an IgG antibody-like molecule comprising a linker that is cleaved by protease, and the antigen binding molecule after cleavage of the linker is VL, VH, or VHH of the antibody or an antigen binding fragment thereof.

[0015b] In another aspect, the present disclosure provides a use of a pharmaceutical composition comprising an antigen binding molecule in the manufacture of a medicament for use in combination therapy for treating a cancer, wherein said medicament is to be administered in combination with a cell expressing a chimeric receptor, wherein

the antigen binding molecule comprises a linker that is cleavable by protease, and has the ability to bind to a target antigen after the cleavage of the linker,

the chimeric receptor comprises an extracellular binding domain, a transmembrane domain and an intracellular signal transduction domain, and the extracellular binding domain has the ability to bind to the antigen binding molecule after the cleavage of the linker, and is capable of binding to a cell expressing the target antigen via binding to the antigen binding molecule after the cleavage of the linker, wherein the antigen binding molecule comprises variable and constant regions of an antibody, and a linker that is cleavable by protease, wherein the antibody is selected from an IgG antibody, an IgG antibody-like molecule and a heavy chain antibody, and the antigen binding molecule obtained through the cleavage of the linker by the protease comprises an antigen binding domain and a portion of the cleaved linker, and a) wherein in the antigen binding molecule, the linker that is cleavable by protease is located near the boundary between the variable region and the constant region or near the boundary between CH1 and CH2 in the constant region, b) wherein in the antigen binding molecule, the linker that is cleavable by protease is located near a hinge region, or c) wherein the antigen binding molecule is an antibody or an IgG antibody-like molecule comprising a linker that is cleaved by protease, and the antigen binding molecule after cleavage of the linker is VL, VH, or VHH of the antibody or an antigen binding fragment thereof.

[0016] The present disclosure provides, for example, a pharmaceutical composition

CLAIMS

1. Use of a pharmaceutical composition comprising a cell expressing a chimeric receptor in the manufacture of a medicament for use in combination therapy for treating a cancer, wherein said medicament is to be administered in combination with an antigen binding molecule, wherein

the antigen binding molecule comprises a linker that is cleavable by protease, and has the ability to bind to a target antigen after the cleavage of the linker, and

the chimeric receptor comprises an extracellular binding domain, a transmembrane domain and an intracellular signal transduction domain, and the extracellular binding domain has the ability to bind to the antigen binding molecule after cleavage of the linker, and is capable of binding to a cell expressing the target antigen via binding to the antigen binding molecule after the cleavage of the linker,

wherein the antigen binding molecule comprises variable and constant regions of an antibody, and a linker that is cleavable by protease, wherein the antibody is selected from an IgG antibody, an IgG antibody-like molecule and a heavy chain antibody, and the antigen binding molecule obtained through the cleavage of the linker by the protease comprises an antigen binding domain and a portion of the cleaved linker, and

a) wherein in the antigen binding molecule, the linker that is cleavable by protease is located near the boundary between the variable region and the constant region or near the boundary between CH1 and CH2 in the constant region,

b) wherein in the antigen binding molecule, the linker that is cleavable by protease is located near a hinge region, or

c) wherein the antigen binding molecule is an antibody or an IgG antibody-like molecule comprising a linker that is cleaved by protease, and the antigen binding molecule after cleavage of the linker is VL, VH, or VHH of the antibody or an antigen binding fragment thereof.

2. Use of a pharmaceutical composition comprising an antigen binding molecule in the

manufacture of a medicament for use in combination therapy for treating a cancer, wherein said medicament is to be administered in combination with a cell expressing a chimeric receptor, wherein

the antigen binding molecule comprises a linker that is cleavable by protease, and has the ability to bind to a target antigen after the cleavage of the linker,

the chimeric receptor comprises an extracellular binding domain, a transmembrane domain and an intracellular signal transduction domain, and the extracellular binding domain has the ability to bind to the antigen binding molecule after the cleavage of the linker, and is capable of binding to a cell expressing the target antigen via binding to the antigen binding molecule after the cleavage of the linker,

wherein the antigen binding molecule comprises variable and constant regions of an antibody, and a linker that is cleavable by protease, wherein the antibody is selected from an IgG antibody, an IgG antibody-like molecule and a heavy chain antibody, and the antigen binding molecule obtained through the cleavage of the linker by the protease comprises an antigen binding domain and a portion of the cleaved linker, and

a) wherein in the antigen binding molecule, the linker that is cleavable by protease is located near the boundary between the variable region and the constant region or near the boundary between CH1 and CH2 in the constant region,

b) wherein in the antigen binding molecule, the linker that is cleavable by protease is located near a hinge region, or

c) wherein the antigen binding molecule is an antibody or an IgG antibody-like molecule comprising a linker that is cleaved by protease, and the antigen binding molecule after cleavage of the linker is VL, VH, or VHH of the antibody or an antigen binding fragment thereof.

3. The use according to claim 1 or 2, wherein a ratio of a K_D value of the antigen binding molecule after cleavage of the linker for the antigen to a K_D value of the antigen binding molecule before cleavage of the linker for the antigen (K_D (after cleavage)/K_D (before cleavage)) is 0.1 or less or 0.01 or less.

4. The use according to any one of claims 1 to 3, wherein the antigen binding molecule is an IgG antibody, an IgG antibody-like molecule, a heavy chain antibody or a single domain antibody.

5. The use according to any one of claims 1 to 4, wherein the antigen binding molecule comprises variable and constant regions of an antibody, and a linker that is cleaved by protease, wherein the antibody is selected from an IgG antibody, an IgG antibody-like molecule and a heavy chain antibody, and the antigen binding molecule obtained through the cleavage of the linker by the protease comprises an antigen binding domain and a portion of the cleaved linker.

6. The use according to any one of claims 1 to 5, wherein in the antigen binding molecule, the linker that is cleaved by protease is located near the boundary between the variable region and the constant region or near the boundary between CH1 and CH2 in the constant region.

7. The use according to any one of claims 1 to 6, wherein the antigen binding molecule is a single domain antibody comprising a linker that is cleaved by protease, and the antigen binding molecule after cleavage of the linker is an antigen binding domain of the single domain antibody and a portion of the linker.

8. The use according to any one of claims 1 to 7, wherein the linker that is cleaved by protease comprises a protease cleavage sequence.

9. The use according to any one of claims 1 to 8, wherein the linker that is cleaved by protease comprises a peptide having any of the protease cleavage sequences of SEQ ID NOs: 1 to 725.